Literature DB >> 12508261

Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome.

Vinod Pullarkat1, Randall D Bass, Jerald Z Gong, Donald I Feinstein, Russell K Brynes.   

Abstract

Myelofibrosis is characterized by reticulin fibrosis of the bone marrow with resulting features of myelophthisis. Besides hematopoietic malignancies and other neoplasms involving the bone marrow, myelofibrosis has been described in association with autoimmune disorders, especially systemic lupus erythematosus. We describe the clinicopathologic features of a primary form of autoimmune myelofibrosis (AIMF) in patients who do not have systemic lupus erythematosus or another well-defined autoimmune syndrome. Absence of marked splenomegaly, peripheral blood cytopenias with mild teardrop poikilocytosis and leukoerythroblastosis, bone marrow lymphoid aggregates, and presence of autoantibodies are some of the salient features of primary AIMF. AIMF should especially be differentiated from chronic idiopathic myelofibrosis, a neoplastic myeloproliferative disease. Primary AIMF appears to have an excellent prognosis, with all patients reported in this series responding to a short course of corticosteroid therapy. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12508261     DOI: 10.1002/ajh.10258

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  26 in total

Review 1.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

2.  Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia.

Authors:  Adam W Mailloux; Ling Zhang; Lynn Moscinski; John M Bennett; Lili Yang; Sean J Yoder; Gregory Bloom; Cody Wei; Sheng Wei; Lubomir Sokol; Thomas P Loughran; Pearlie K Epling-Burnette
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

3.  Primary autoimmune myelofibrosis with severe thrombocytopenia mimicking immune thrombocytopenia: A case report.

Authors:  Jian Hua; Shu Matayoshi; Tomoyuki Uchida; Morihiro Inoue; Masao Hagihara
Journal:  Mol Clin Oncol       Date:  2016-10-26

4.  A rare cause of cytopenia in a patient with systemic lupus erythematosus: Autoimmune myelofibrosis.

Authors:  Döndü Üsküdar Cansu; Hava Üsküdar Teke; Cengiz Korkmaz
Journal:  Eur J Rheumatol       Date:  2017-03-01

Review 5.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

6.  Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF-β in the bone marrow: a case report.

Authors:  Hiroshi Ohkawara; Miki Furukawa; Kazuhiko Ikeda; Akiko Shichishima-Nakamura; Masahiko Fukatsu; Takahiro Sano; Koki Ueda; Satoshi Kimura; Risa Kanai; Yuka Oka; Fumi Murakami; Osamu Suzuki; Yuko Hashimoto; Kazuei Ogawa; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2017-06-05       Impact factor: 2.490

7.  Primary autoimmune myelofibrosis: a case report and review of the literature.

Authors:  Yasmin Abaza; C Cameron Yin; Carlos E Bueso-Ramos; Sa A Wang; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2016-11-09       Impact factor: 2.490

8.  Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus.

Authors:  Nabil Belfeki; Gopinath Shankarasivam; Damienne Declerck; Sylvain Diamantis
Journal:  BMJ Case Rep       Date:  2019-01-14

Review 9.  Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications.

Authors:  Aziz Nazha; Joseph D Khoury; Raajit K Rampal; Naval Daver
Journal:  Oncologist       Date:  2015-08-24

10.  PRCA with myelofibrosis: an unusual case report.

Authors:  Rakhee Kar; Manoranjan Mahapatra; Hara P Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2008-05-01       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.